Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
CLL16
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
- NCT05197192 ↗
- Recruiting
- German CLL Study Group
- Deep
We haven't built an HCP commentary report on CLL16 (obinutuzumab, venetoclax and 1 more in Chronic Lymphocytic Leukemia) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CLL16 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 14 | |
| Podcasts | 8 | |
| X threads | 5 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Prospective, Open-label, Multicentre, Randomized, Phase-3-trial of Acalabrutinib, Obinutuzumab and Venetoclax (GAVE) Compared to Obinutuzumab and Venetoclax (GVE) in Previously Untreated Patients With High Risk Chronic Lymphocytic Leukemia (CLL)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Obinutuzumab; Venetoclax; Acalabrutinib
- Arms
- GAVe-Arm · Experimental
- GVe-Arm · Experimental
- Enrollment
- 202 (estimated)
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- German CLL Study Group with AstraZeneca
- Start
- Apr 19, 2022
- Primary completion
- May 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05197192 · updated Aug 20, 2026